Next On Medicare’s To Do List For Alzheimer’s: Coverage Of PET Scans And Genetic Testing
Medicare policymakers have felt that without an effective approved treatment, coverage of amyloid PET scans and APOE4 genetic tests was not warranted. But that is changing.
You may also be interested in...
After a decade of curtailed use, new drugs make wider availability important for patient selection and safety, CMS says in a new amyloid PET scan proposal.
There is no fee to participate, and entries to the registry must be made at baseline and then every six months for up to two years.
Labeling for the first anti-amyloid to receive traditional approval in Alzheimer’s disease states that testing for ApoE ε4 status ‘should be performed’ prior to treatment; updated labeling also includes stronger cautionary language on use in patients with risk factors for cerebral hemorrhage.